17 completed, 7 withdrawn, 1 terminated, 1 unknown. 26 Phase 2, 5 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 17, Withdrawn 7, Terminated 1, Unknown 1 |
| Phase 3 | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Heroin Dependence: new trials by email Literature Review of Heroin Dependence trials Research Report on Heroin Dependence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neuroimaging and CBD for Opioid Use Disorder Cannabidiol (CBD), Placebo - Heroin Abuse, Opioid Use Disorder | Phase 2 | Completed | Yasmin Hurd | 66 | 2020-11-12 | 2025-10-27 |
| Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose - Heroin Dependence, Opioid Use Disorder | Phase 1 / Phase 2 | Completed | Wayne State University | 26 | 2016-12-01 | 2020-11-10 |
| Pioglitazone for Heroin and for Nicotine Dependence PIO, Placebo - Heroin Dependence, Nicotine Dependence | Phase 1 / Phase 2 | Terminated | New York State Psychiatric Institute | 82 | 2011-03-01 | 2017-07-13 |
| Study of Computer-Based Treatment for Drug Dependence Recovery Line Support System - Opioid-Related Disorders, Heroin Dependence | Phase 2 | Completed | Yale University | 36 | 2010-07-01 | 2020-04-02 |
| Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India Directly Administered Antiretroviral Therapy (DAART), SAT - HIV Infections, Heroin Dependence | Phase 2 / Phase 3 | Withdrawn | Johns Hopkins University | 2008-07-01 | 2015-04-15 | |
| Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Vivitrol, memantine - Opioid Dependence, Heroin Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 82 | 2008-06-01 | 2018-07-17 |
| Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction CRAFT-T, Treatment as usual - Heroin Dependence, Opiate Dependence | Phase 1 / Phase 2 | Unknown | University of Cincinnati | 104 | 2008-03-01 | 2012-08-14 |
| Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial Buprenorphine - Opioid-Related Disorders, Heroin Dependence | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 20 | 2007-12-01 | 2019-04-24 |
| Addiction Treatment in Russia: Oral vs. Naltrexone Implant naltrexone implant, oral naltrexone, oral placebo naltrexone - Heroin Dependence, Opioid-Related Disorders | Phase 2 / Phase 3 | Completed | University of Pennsylvania | 306 | 2006-07-01 | 2019-03-18 |
| Directly Administered HIV Therapy in Methadone Clinics Directly administered antiretroviral therapy (DAART) - HIV Infections, Heroin Dependence | Phase 2 / Phase 3 | Completed | Johns Hopkins University | 107 | 2006-04-01 | 2015-04-15 |
| Naltrexone and Adrenergic Agents to Reduce Heroin Use in Heroin Addicts Naltrexone, Placebo - Heroin Dependence | Phase 2 | Completed | Baylor College of Medicine | 301 | 2006-02-01 | 2012-10-24 |
| Addition of Naltrexone to Methadone Taper Naltrexone, Placebo comparator, naltrexone - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 174 | 2005-04-01 | 2017-01-12 |
| Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6 Test Drug, Placebo Drug - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Withdrawn | University of Colorado, Denver | 2002-12-01 | 2017-05-04 | |
| Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence depot naltrexone, Compliance enhancement (CE), BNT - Opiate Dependence | Phase 2 | Completed | New York State Psychiatric Institute | 125 | 2002-06-01 | 2012-10-26 |
| Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens Levoacetyl Methadol - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Completed | National Institute on Drug Abuse (NIDA) | 142 | 2001-11-01 | 2017-01-12 |
| Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1 Buprenorphine - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Completed | Yale University | 2000-08-01 | 2020-06-29 | |
| Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 Opioid-Related Disorders - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Withdrawn | University of Colorado, Denver | 1999-10-01 | 2017-05-04 | |
| Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1 Naltrexone, Behavioral Naltrexone Therapy (BNT), Compliance Enhancement (CE) - Heroin Dependence | Phase 2 | Completed | New York State Psychiatric Institute | 12 | 1999-08-01 | 2012-01-13 |
| Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4 Opioid-Related Disorders - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Withdrawn | University of Colorado, Denver | 1999-04-01 | 2017-05-04 | |
| Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3 Opioid-Related Disorders - Heroin Dependence, Opioid-Related Disorders | Phase 2 | Withdrawn | University of Colorado, Denver | 1997-07-01 | 2017-05-04 |
Showing 20 of 26. Sign in to see all of them.
Opioid-Related Disorders (20) · Substance-Related Disorders (8) · Cocaine-Related Disorders (2) · HIV Infections (2) · Substance Abuse, Intravenous (1) · Tobacco Use Disorder (1)
Chemically-Induced Disorders (26) · Mental Disorders (26) · Narcotic-Related Disorders (26) · Substance-Related Disorders (18) · Opioid-Related Disorders (6) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Infections (2) · Lentivirus Infections (2) · RNA Virus Infections (2) · Retroviridae Infections (2) · Sexually Transmitted Diseases (2)
Buprenorphine (6) · Naltrexone (4) · Methadyl Acetate (2) · Cannabidiol (1) · Drug Evaluation (1) · Fentanyl (1) · Memantine (1) · Methadone (1) · Morphine (1) · Naloxone (1) · Opiate Alkaloids (1) · Oxycodone (1) · Pioglitazone (1) · Therapeutics (1) · vivitrol (1)
New York State Psychiatric Institute (6) · University of Colorado, Denver (6) · National Institute on Drug Abuse (NIDA) (5) · Johns Hopkins University (2) · Yale University (2) · Baylor College of Medicine (1) · University of Cincinnati (1) · University of Pennsylvania (1) · Wayne State University (1) · Yasmin Hurd (1)
United States (24) · Russia (2) · India (1)
Leslie Amass, Ph.D. (6) · Jack Mendelson, M.D. (2) · Adam Bisaga, MD (1) · Alison Oliveto, Ph.D. (1) · Brent A. Moore, Ph.D. (1) · Edward Nunes, M.D. (1) · Edward Nunes, MD (1) · Erik W Gunderson, M.D. (1) · George Woody, MD (1) · Gregory M Lucas, MD,PhD (1) · Gregory M. Lucas, MD, PhD (1) · Gregory S. Brigham, Ph.D. (1) · Herbert Kleber, M.D. (1) · John Grabowski, PhD (1) · Mark Greenwald, PhD (1)
PMID 16002025, PMID 16870915, PMID 17581533, PMID 17933486, PMID 19283561, PMID 20631574, PMID 21513688, PMID 21715107, PMID 22233189, PMID 23572466, PMID 23874575, PMID 27436632, PMID 33140460, PMID 40342086, PMID 40833692
R01DA011160 (6), R01DA010746 (2), K01DA022398 (1), K23DA020000 (1), K23DA021512 (1), P50DA009236 (1), R01DA009803 (1), R01DA015822 (1), R01DA017317 (1), R01DA018863 (1), R01DA031022 (1)